A randomized trial of adjuvant chemotherapy and immunotherapy in Stage I and Stage II cutaneous melanoma. An interim report

Cancer. 1985 Feb 15;55(4):707-12. doi: 10.1002/1097-0142(19850215)55:4<707::aid-cncr2820550406>3.0.co;2-5.


Seventy patients with Stage I and II malignant melanoma were randomized to treatment with either intravenous dacarbazine alone or intravenous dacarbazine plus intradermal injection of the methanol-extracted residue of bacillus Calmette-Guerin (BCG). Analysis of treatment failed to reveal a statistically significant difference between these two forms of treatment in Stage I and II patients. It is possible that chemoimmunotherapy may increase survival in Stage II patients, but this possibility should be interpreted with caution.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • BCG Vaccine / therapeutic use*
  • Combined Modality Therapy
  • Dacarbazine / administration & dosage
  • Dacarbazine / therapeutic use*
  • Female
  • Humans
  • Male
  • Melanoma / pathology
  • Melanoma / therapy*
  • Middle Aged
  • Neoplasm Metastasis
  • Random Allocation
  • Skin Neoplasms / pathology
  • Skin Neoplasms / therapy*


  • BCG Vaccine
  • Dacarbazine